Fresenius Kabi is expanding it's leading market position in South Africa

Fresenius Kabi, a company of the Fresenius healthcare group, is continuing to expand its market position in South Africa. The European leader in infusion and nutrition therapy today announced that it has acquired Isotec Nutrition from Alliance Pharmaceuticals and the general manager of Isotec, who will continue to hold an executive position. Isotec Nutrition is specialized in compounding and sales of infusion solutions for parenteral (= via the vein) nutrition. Isotec already has a longstanding sales and marketing relationship with Fresenius Kabi South Africa. In 2003, Isotec Nutrition had sales of approx. 10 million €.

Fresenius Kabi is successfully operating in South Africa with its own subsidiary since March 1999 and is the market leader in the areas of parenteral nutrition, generic IV drugs and blood volume substitution. In 2000, Fresenius Kabi acquired Intramed, the leading supplier of standard infusion solutions in South Africa. In addition, Fresenius Kabi has successfully launched products of its enteral nutrition program.

With the acquisition of Isotec Nutrition, Fresenius Kabi further strengthens it's leading position in the field of parenteral nutrition in the South African market. Furthermore, the company completes its product range in the field of infusion and nutrition therapy and has a strong platform for future growth not only in South Africa, but in the whole southern part of the continent. With a population of approximately 200 million people, the southern part of Africa is an important international growth market for Fresenius Kabi.